Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Grifols International
Deal Size : $6.2 million
Deal Type : Acquisition
Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.
Details : Grifols, S.A.will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $3.2 million
February 21, 2020
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Grifols International
Deal Size : $6.2 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?